Aclaris Therapeutics, Inc. (ACRS) Financial Statements (2023 and Earlier)

Company Profile

Business Address 640 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:225,70054,10075,015167,972208,854174,13492,038
Cash and cash equivalents27,34922,063  20,20230,1719,851
Short-term investments164,06532,06839,078110,953173,655107,05175,017
Other undisclosed cash, cash equivalents, and short-term investments34,286(31)35,93757,01914,99736,9127,170
Receivables6237727044,861481  
Inventory, net of allowances, customer advances and progress billings   791   
Inventory   791   
Deferred costs     116 
Disposal group, including discontinued operation  4,966    
Assets held-for-sale, not part of disposal group      216
Other undisclosed current assets(21,291)2,6213,1185,875(9,114)(35,694)(5,730)
Total current assets:205,03257,49383,803179,499200,221138,55686,524
Noncurrent Assets
Property, plant and equipment1,3351,6542,4704,2802,159481360
Long-term investments and receivables34,242   14,99736,9127,170
Long-term investments34,242   14,99736,9127,170
Intangible assets, net (including goodwill)7,0487,1237,19991,45525,853  
Goodwill   18,50418,504  
Intangible assets, net (excluding goodwill)7,0487,1237,19972,9517,349  
Other noncurrent assets3,5544,5144,8253322792022
Other undisclosed noncurrent assets     116 
Total noncurrent assets:46,17913,29114,49496,06743,28837,5297,552
TOTAL ASSETS:251,21170,78498,297275,566243,509176,08594,076
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,03611,16017,63827,34212,7626,2231,555
Accounts payable9,9855,2549,91714,7557,8222,845810
Accrued liabilities10,0515,9067,72112,5874,9403,378745
Disposal group, including discontinued operation2,2023,1114,157    
Other liabilities693603637    
Total current liabilities:22,93114,87422,43227,34212,7626,2231,555
Noncurrent Liabilities
Long-term debt and lease obligation 2,894     
Operating lease, liability 2,894 
Liabilities, other than long-term debt30,9397,6075,9533,1865,485  
Deferred tax liabilities, net549549  
Deferred income tax liabilities367367549
Other liabilities2,1723,1793,7361,703558  
Business combination, contingent consideration, liability28,4004,0611,6689344,378  
Other undisclosed noncurrent liabilities 7,759 29,914 372 
Total noncurrent liabilities:30,93918,2605,95333,1005,485372 
Total liabilities:53,87033,13428,38560,44218,2476,5951,555
Stockholders' equity
Stockholders' equity attributable to parent197,34137,65069,912215,124225,262169,49092,521
Common stock1      
Additional paid in capital792,971542,286523,505507,366384,943260,671135,503
Accumulated other comprehensive loss(224)(94)(66)(69)(246)(269)(149)
Accumulated deficit(595,407)(504,542)(453,527)(292,173)(159,435)(90,912)(42,833)
Total stockholders' equity:197,34137,65069,912215,124225,262169,49092,521
TOTAL LIABILITIES AND EQUITY:251,21170,78498,297275,566243,509176,08594,076

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues6,7616,4824,22710,0911,683  
Revenue, net1,683  
Cost of revenue(4,713)(5,133)(4,055)(6,850)(1,207)  
Gross profit:2,0481,3491723,241476  
Operating expenses(67,432)(52,261)(111,230)(138,655)(72,899)(48,567)(20,667)
Other undisclosed operating loss(24,339)      
Operating loss:(89,723)(50,912)(111,058)(135,414)(72,423)(48,567)(20,667)
Nonoperating income (expense)(1,142)(424)(2,484)2,6762,070488104
Investment income, nonoperating      104
Other nonoperating income (expense)(1,142)(424)(2,484)2,6762,070488 
Interest and debt expense(752)(5)(87)    
Other undisclosed income from continuing operations before equity method investments, income taxes 144     
Loss from continuing operations before equity method investments, income taxes:(91,617)(51,197)(113,629)(132,738)(70,353)(48,079)(20,563)
Other undisclosed income (loss) from continuing operations before income taxes752(139)(47,725)    
Loss from continuing operations before income taxes:(90,865)(51,336)(161,354)(132,738)(70,353)(48,079)(20,563)
Income tax benefit 182  1,830  
Loss from continuing operations:(90,865)(51,154)(161,354)(132,738)(68,523)(48,079)(20,563)
Income from discontinued operations 139     
Net loss attributable to parent:(90,865)(51,015)(161,354)(132,738)(68,523)(48,079)(20,563)
Preferred stock dividends and other adjustments      (2,566)
Net loss available to common stockholders, diluted:(90,865)(51,015)(161,354)(132,738)(68,523)(48,079)(23,129)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(90,865)(51,015)(161,354)(132,738)(68,523)(48,079)(20,563)
Other comprehensive income (loss)(130)(28)317723(120)(143)
Comprehensive loss, net of tax, attributable to parent:(90,995)(51,043)(161,351)(132,561)(68,500)(48,199)(20,706)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: